Please login to the form below
Amag
This page shows the latest Amag news and features for those working in and with pharma, biotech and healthcare.
Amag buys into maternal health business
Meanwhile, another key driver of the deal is thought to be the potential to push sales of Lumara's drug using Amag's commercial base. ... Under the terms of the acquisition, Lumara will operate as a separate business within Amag reporting to the Amag's
Latest news
-
Death leads to recall of batch of Takeda's Rienso in Switzerland
As reported by Reuters, Amag's shares were down about 5 per cent following the recall announcement. ... Both Amag and Takeda are now investigating the Swiss batch of Rienso, while the introduction of new batches will depend on approval by Swiss health
-
Oncology bias in pharma deals
Newron should receive a $2m termination fee from Biotie. The $179m merger between oncology company, Allos Therapeutics and AMAG Pharmaceuticals announced in July, was terminated when AMAG shareholders rejected the deal ... 2 ##. Allos Therapeutics/AMAG
-
Dermatology developments
One of the Amag investors, the hedge fund MSMB, strongly opposed the merger and made a bid of $381m for Amag. ... Retin-A and Renova. Launched. 345. Amag/Allos. Amag merges with Allos, pays $268m to Allos shareholders.
-
Orphan drug focus
318. AMAG Pharmaceuticals/ Takeda. feraheme (ferumoxytol) - for iron deficiency anaemia.
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Acquisition - business unit. 1, 045. EndoCeutics/ AMAG Pharmaceuticals. Intraros (prasterone), non-oestrogen product for postmenopausal atrophic vaginitis (FDA approved), female sexual dysfunction (phase III).
-
Deal Watch January 2017
500. Palatin Technologies. AMAG Pharmaceutical. Exclusive licence for N. America. Rekynda (bremelanotide) for sexual disorder p3.
-
Deal Watch table for September 2014
1, 750. Lumara Health / Amag. Lumara Health / Perrigo. Company acquisition (excluding Perrigo products).
-
Pharma deals during September 2014
Amag is buying the remaining company for up to $1.025bn. It contains Makena, a progesterone injection with US orphan status to reduce the risk of preterm birth with annual sales
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
She joins Orchard from AMAG Pharmaceuticals, where she served as senior vice president, corporate affairs, directing the company’s communications, government relations and advocacy activities.
-
Merck appoints new North America and China biopharma leaders
Zieziula brings over 30 years of pharmaceutical experience to the role, having held senior management positions at Amag Pharmaceuticals, Bristol Myers-Squibb, MSD and Roche, before joining Merck in 2015 as
-
Spectrum appoints chief medical officer
Lee Allen joins from AMAG Pharmaceuticals. Dr Lee Allen has joined cancer-focused Spectrum Pharmaceuticals as chief medical officer. ... 2013. The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
